THE National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand have released the Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025.
The update from the 2016 guideline provides recommendations based on contemporary evidence to support healthcare professionals, including pharmacists, in delivering the best possible care to people experiencing acute coronary syndromes (ACS).
ACS includes acute myocardial infarction (AMI) and unstable angina (UA), resulting from inadequate blood flow to heart muscle, and remains a leading cause of illness and death.
The updated guideline introduces major advancements in diagnosing and treating heart attacks and angina, helping to improve outcomes for patients across Australia.
It also addresses recovery after ACS and secondary prevention of future vascular events.
Advanced Pharmacy Australia (AdPha) has recognised the role of Adam Livori, AdPha member and past Chair of the Cardiology Leadership Committee, for his valuable contributions to the new guideline.
Livori represented the pharmacy sector on the ACS Guideline Reference Group and also played a key role in the ACS Guideline Hospital Care and Reperfusion Expert Subgroup.
Access the guideline HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Apr 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Apr 25
